Tafluprost acid Inhibitor

MBS5756357 is an inhibitor targeting Tafluprost acid. Tafluprost acid is a selective agonist at the prostaglandin F receptor.

Krupa M, ChodyA, ski M, Ostaszewska A, Cmoch P, Dams I. A Novel Convergent Synthesis of the Potent Antiglaucoma Agent Tafluprost. Molecules. 2017 Jan 31;22(2). pii: E217. doi: 10.3390/molecules22020217. PubMed PMID: 28146132.
Fuwa M, Ueda K, Akaishi T, Yamashita N, Kirihara T, Shimazaki A, Mano H, Kawazu K. Advantages of Efficacy and Safety of Fixed-Dose Tafluprost/Timolol Combination Over Fixed-Dose Latanoprost/Timolol Combination. PLoS One. 2016 Jul 6;11(7):e0158797. doi: 10.1371/journal.pone.0158797. eCollection 2016. PubMed PMID: 27383260; PubMed Central PMCID: PMC4934872.
Kaarniranta K, Ikaheimo K, Mannermaa E, Ropo A. Pharmacokinetics, Efficacy, and Safety of the Preservative-free Fixed Combination of Tafluprost 0.0015% and Timolol 0.5% in Healthy Volunteers: A Phase I Comparison vs. the Corresponding Preservative-free Monotherapies. Clin Pharmacokinet. 2016 Apr;55(4):485-94. doi: 10.1007/s40262-015-0331-x. PubMed PMID: 26391697.
Akaishi T, Shimazaki A, Tonouchi A, Ueda K, Miyawaki N, Kawazu K. Benefits of Tafluprost and Timolol Fixed-Dose Combination for the treatment,of Glaucoma Are Confirmed by Studies on Experimental Animal Models. J Ocul Pharmacol Ther. 2015 Nov;31(9):518-24. doi: 10.1089/jop.2015.0031. Epub 2015 Sep 1. PubMed PMID: 26325164.

Small volumes of Tafluprost acid, inhibitor vial(s) may occasionally become entrapped in the seal of the product vial during shipment and storage. If necessary, briefly centrifuge the vial on a tabletop centrifuge to dislodge any liquid in the container`s cap. Certain products may require to ship with dry ice and additional dry ice fee may apply.